Rapid Micro Biosystems Reports Q2 Revenue Growth & Record Gross Margin, Reaffirms 2026 Guidance
RPID sits 25% above its 52-week low of $1.66.
Summary
Rapid Micro Biosystems announced Q2 2026 results with 11% revenue growth and a record 15% gross margin, while reaffirming full-year revenue and gross margin guidance and raising system validation targets.
Key Events · Earnings and Guidance · RPID
-
Q2 Revenue Growth
Total revenue increased 11% year-over-year to $8.1 million for the second quarter ended June 30, 2026.
-
Record Gross Margin Achieved
The company reported a record Q2 gross margin of 15%, a significant increase from 3.8% in the second quarter of 2025, reflecting meaningful progress in margin expansion initiatives.
-
Increased System Validation Guidance
Full-year 2026 system validation guidance was increased to at least 27 validations, up from 25 previously.
-
Full-Year Guidance Reaffirmed
Rapid Micro Biosystems reaffirmed its full-year 2026 total revenue guidance of $37.0 million to $41.0 million and gross margin percentage of approximately 20%.
Analysis · RPID · Industrial Applications And Services
Rapid Micro Biosystems reported an 11% increase in Q2 revenue and a significant improvement in gross margin, reaching a record 15% compared to 3.8% last year. This operational progress is crucial for the company's path to profitability, especially following a recent dilutive offering. While net loss widened and cash burn continues, the raised guidance for system validations indicates positive momentum in customer adoption.
At the time of this filing, RPID was trading at $2.08 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $103.6M. The 52-week trading range was $1.66 to $4.94. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.